Research programme: nanoparticle therapeutics - Biodexa Pharmaceuticals
Alternative Names: Gold nanoparticle encapsulated therapeutics - Biodexa Pharmaceuticals; Immuno-oncology TAM MTR- Biodexa Pharmaceuticals; Immuno-oncology vaccine MTR - Biodexa Pharmaceuticals; MTECHR 01; MTECHT 02; MTECHT 03; MTECHV 02; Nanoparticle bound amoxicillin - Biodexa PharmaceuticalsLatest Information Update: 16 May 2023
At a glance
- Originator Midatech
- Developer Biodexa Pharmaceuticals; Dana-Farber Cancer Institute
- Class Cancer vaccines; Conjugate vaccines; Viral vaccines
- Mechanism of Action Cell wall inhibitors; Immunostimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections; Cancer; Glioblastoma; Viral infections
Most Recent Events
- 28 May 2019 No recent reports of development identified for research development in Glioblastoma in United Kingdom
- 28 May 2019 No recent reports of development identified for research development in Glioblastoma in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in United Kingdom